Company: Catalyst Biosciences
Job title: Vice President Translational Research
Grant Blouse has served as Vice President of Translational Research at Catalyst since July 2018. Previously, Dr. Blouse was Principle Scientist and Project Manager at Novo Nordisk A/S, Haemophilia Enzymology, where he led early and late stage hemophilia projects and drove the strategic evaluation of new therapeutic areas in the rare disease space. Prior to Novo Nordisk, Dr. Blouse was a Senior Scientist at Catalyst Biosciences where he helped build Catalyst’s next-generation hemophilia franchise, including identification of Catalyst’s Factor VIIa candidate marzeptacog alfa (activated) and co-inventing its Factor IX candidate CB 2679d/ISU304. Dr. Blouse has held research and investigator positions at Aarhus University’s Department of Molecular Biology, Henry Ford Health System’s Division of Biochemical Research and Wayne State University School of Medicine’s Department of Pharmacology.
Dr. Blouse has authored more than 50 peer reviewed papers and abstracts and delivered more than a dozen invited talks in the biochemistry and hematology spaces.
Dr. Blouse earned his B.A. in Anthropology from the University of Delaware, his M.Sc. in Biochemistry from Clemson University and his Ph.D. in Pharmacology from Wayne State University School of Medicine.
Hemophilia B Gene Therapy in Mice Using a Novel Chimeric AAV Capsid Combined with a Potency Enhanced FIX Variant 2:45 pm
Advantages of next generation AAV capsids combined with transgenes having increased functionality to lower vector doses Developing a novel AAV vector technology to reduce systemic payload of hemophilia B gene therapies Discussing pre-clinical data on the performance of the novel technologyRead more
day: Day One